IFM Investors Pty Ltd Raises Holdings in Hologic, Inc. (HOLX)

IFM Investors Pty Ltd increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 12.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,832 shares of the medical equipment provider’s stock after buying an additional 1,703 shares during the period. IFM Investors Pty Ltd’s holdings in Hologic were worth $649,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HOLX. Piedmont Investment Advisors LLC acquired a new stake in shares of Hologic in the second quarter valued at approximately $127,000. Amussen Hunsaker Associates LLC acquired a new stake in shares of Hologic in the second quarter valued at approximately $159,000. Lincoln Capital Corp acquired a new stake in shares of Hologic in the third quarter valued at approximately $201,000. Homrich & Berg acquired a new stake in shares of Hologic in the second quarter valued at approximately $204,000. Finally, Granite Springs Asset Management LLC acquired a new stake in shares of Hologic in the second quarter valued at approximately $206,000. Institutional investors own 98.91% of the company’s stock.

A number of research analysts recently issued reports on the stock. BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 25th. Morgan Stanley decreased their price objective on shares of Hologic from $47.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 11th. Zacks Investment Research cut shares of Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. UBS Group assumed coverage on shares of Hologic in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $44.00 price objective on the stock. Finally, Canaccord Genuity lifted their price objective on shares of Hologic from $40.00 to $41.00 and gave the company a “hold” rating in a research note on Thursday, September 27th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $44.47.



In other Hologic news, Director Sally Crawford sold 13,257 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $39.54, for a total transaction of $524,181.78. Following the sale, the director now owns 167,701 shares of the company’s stock, valued at $6,630,897.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christiana Stamoulis sold 30,967 shares of the business’s stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $40.70, for a total transaction of $1,260,356.90. Following the sale, the director now directly owns 66,006 shares in the company, valued at approximately $2,686,444.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 47,661 shares of company stock worth $1,927,174. Insiders own 0.88% of the company’s stock.

Shares of NASDAQ:HOLX opened at $38.65 on Wednesday. The company has a market capitalization of $10.40 billion, a P/E ratio of 19.04, a PEG ratio of 1.74 and a beta of 0.67. The company has a current ratio of 1.29, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. Hologic, Inc. has a 1 year low of $35.10 and a 1 year high of $45.09.

Hologic (NASDAQ:HOLX) last posted its earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.02. The firm had revenue of $824.00 million for the quarter, compared to analysts’ expectations of $800.14 million. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. As a group, equities analysts predict that Hologic, Inc. will post 2.24 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Stock Split

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply